New insights in the treatment of DKD: recent advances and future prospects

作者：Meimei Zhao, Yongtong Cao, Liang Ma · 发表于：BMC Nephrology · 年份：2025 · DOI：10.1186/s12882-025-03953-3 · 被引用次数：20 · 研究领域：Diabetes Treatment and Management、Pharmacology and Obesity Treatment、Restless Legs Syndrome Research

Diabetic kidney disease (DKD) represents the predominant and severe microvascular complication associated with diabetes, frequently culminating in End-Stage Kidney Disease (ESKD). The escalating prevalence of diabetes has correspondingly led to a rise in DKD incidence, imposing significant challenges on both individuals and society. The etiology of DKD is multifaceted and remains devoid of definitive therapeutic interventions. This article examines the pharmacological actions and mechanisms of different drugs used for the prevention and treatment of DKD that are currently in clinical use or undergoing development. The goal is to offer insights for early intervention based on therapeutic combinations to potentially slow kidney disease progression.